Abstract
Recent retrospective studies have suggested that increased ventricular repolarization heterogeneity (VRH), a predictor of poor cardiovascular prognosis, in patients with type 2 diabetes (T2DM) is reversed by treatment with an SGLT2 inhibitor, but not by other hypoglycemic agents. However, to our knowledge, no study in the literature has prospectively examined the effect of an SGLT2 inhibitor on T2DM-induced VRH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
